Ionic Liquid-Incorporated Lipid Nanoparticles for BBB Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing lipid nanoparticles (LNPs) face challenges in effectively delivering drugs to hard-to-reach targets like the brain due to high accumulation in non-target organs such as the liver and spleen, limiting their therapeutic potential for brain diseases.
Innovation Solution
Derivatizing LNPs with ionic liquids, specifically replacing PEG-DMG with ionic components like choline trans-2-hexenoate, to enhance their ability to cross the Blood-Brain Barrier (BBB) and redirect drug delivery away from clearance organs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional LNPs are used for drug delivery, then they can effectively deliver drugs to systemic circulation, but they accumulate in non-target organs (liver and spleen) and cannot cross the Blood-Brain Barrier
Solution Approach 1:
The patent changes the surface chemistry parameters of LNPs by incorporating ionic liquids with specific cations (choline, betaine, phosphocholine) and anions (carboxylic acid derivatives). This parameter change modifies the LNP surface properties to enable BBB penetration while reducing reticuloendothelial system uptake, thereby resolving the contradiction between brain delivery reliability and harmful accumulation in clearance organs
Solution Approach 2:
The patent creates composite LNP structures by integrating ionic liquid components into the LNP formulation. The composite material combines the core LNP delivery mechanism with ionic liquid surface modifications, enabling dual functionality: maintaining systemic circulation capability while gaining BBB penetration ability and reducing liver/spleen accumulation
2Reliability
If PEG-DMG is used as the ionic component in LNPs, then the LNPs have stable circulation, but they lack the ability to cross the Blood-Brain Barrier
Solution Approach 1:
The patent systematically varies the ionic liquid composition parameters, testing different cations (choline, betaine, phosphocholine) and anions (trans-2-hexenoate, other carboxylic acid derivatives) to identify combinations that provide both BBB penetration capability and formulation stability. The optimal choline trans-2-hexenoate ionic liquid emerges from this parameter optimization, balancing BBB crossing ability with LNP compositional stability
3Reliability
If LNPs are modified to cross the BBB, then brain delivery is improved, but the complexity of the formulation increases
Solution Approach 1:
The patent integrates ionic liquid functionality directly into the LNP formulation as a composite material, rather than adding separate complex targeting modules. The ionic liquid components serve multiple functions simultaneously: surface modification for BBB penetration, stability enhancement, and reduced off-target accumulation, thereby achieving improved brain delivery without proportionally increasing formulation complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
IL-LNPs demonstrate improved BBB penetration and reduced liver and spleen accumulation, facilitating effective drug delivery to the brain by hitchhiking on red blood cells, thus overcoming the limitations of conventional LNPs.
Implementation Method 1
facilitating effective drug delivery to the brain by hitchhiking on red blood cells
Data Source
AI summary
The present invention is an improvement in Lipid Nanoparticles (LNPs) for re-routing their distribution from the liver and spleen (the non-target organs) to hard-to-deliver targets such as the brain and other tissues for drug delivery. Specifically, the invention derivatizes or otherwise modifies LNPs to provide the surface or constituency thereof with “Ionic Liquid” (IL) so that the IL-LNP incorporates an ionizable lipid such as a cationic ionizable lipid, an optional helper lipid, cholesterol and a (true) ionic liquid component. Among other benefits of the inclusion of “Ionic Liquid” is to decrease the delivery of LNPs to the body's filtering organ—the liver—and thereby re-route delivery to other target organs.